Director John Ketchum of Tango Therapeutics, Inc. filed a Form 144 notice of proposed sale on November 17, 2026, disclosing plans to sell 7,590 shares of common stock on NASDAQ.
Key Highlights
- Seller and role: John Ketchum, listed as a Director of Tango Therapeutics, Inc.
- Shares proposed for sale: 7,590 shares of common stock, with an aggregate market value of $183,450.30 according to the filing.
- Shares outstanding: 169,455,160 shares of common stock were reported outstanding at the time of filing.
- Source of shares: The securities were acquired through restricted stock units granted by the issuer, with an acquisition date of August 19, 2024.
- Rule 10b5-1 plan: The filing indicates a trading plan or instruction date of August 18, 2026.
- Approximate sale date: November 17, 2026, through broker Morgan Stanley Smith Barney LLC Executive Financial Services.
- No sales in prior three months: The filing reports nothing to report under the securities sold during the past three months section.
Ketchum's Proposed Share Sale: RSU Vesting and Plan Details
According to the Form 144 filing submitted to the U.S. Securities and Exchange Commission, John Ketchum, a director of Tango Therapeutics, Inc. (NASDAQ:TNGX), intends to sell 7,590 shares of the company's common stock. The filing lists the aggregate market value of the shares to be sold as $183,450.30, based on 169,455,160 total shares of common stock outstanding at the time of the notice.
The filing discloses that the shares to be sold were originally acquired as restricted stock units from the issuer, with an acquisition date of August 19, 2024, and a payment date also listed as August 19, 2024, with the nature of payment noted as "N/A." The remarks section of the filing states: "The securities to be sold were acquired upon the vesting of restricted stock units during the period of 8/19/2024 through 8/17/2026." The proposed sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.
The filing further indicates that Ketchum is relying on a Rule 10b5-1 plan or instruction, with a plan adoption or instruction date of August 18, 2026. By signing the form, the filer represents that, as of the plan adoption date, he did not know of any material adverse information regarding the current and prospective operations of Tango Therapeutics that had not been publicly disclosed. The filing reports no sales of Tango Therapeutics securities by Ketchum in the three months preceding the notice date.
What Was Disclosed
Tango Therapeutics director John Ketchum filed a Form 144 on November 17, 2026, proposing the sale of 7,590 common shares acquired via restricted stock unit vesting, with an aggregate market value of $183,450.30, through a Rule 10b5-1 plan adopted August 18, 2026.






Please wait processing your request...